Breaking News
February 17, 2019 - MUSC researchers discover new mechanism for a class of anti-cancer drugs
February 17, 2019 - HPV misconceptions are causing women to miss smear tests
February 17, 2019 - Sanofi and Regeneron Offer Praluent (alirocumab) at a New Reduced U.S. List Price
February 17, 2019 - Researchers say auditory testing can identify children for autism screening
February 17, 2019 - New method analyzes how single biological cells react to stressful situations
February 17, 2019 - WVU gynecologic oncologist investigates novel treatment for cervical and vaginal cancers
February 17, 2019 - ADHD diagnoses poorly documented
February 17, 2019 - Majority of gender minority youth do not identify with traditional sexual identity labels
February 17, 2019 - AbbVie, Teneobio enter into strategic transaction to develop potential treatment for multiple myeloma
February 17, 2019 - Lower Birth Weight May Up Risk for Psychiatric Disorders
February 17, 2019 - Scientists identify reversible molecular defect underlying rheumatoid arthritis
February 17, 2019 - Moffitt researchers shed light on how CAR T cells function mechanistically
February 16, 2019 - Female Anatomy May Play Big Role in Sperm’s Success
February 16, 2019 - BMI may mediate inverse link between fiber intake, knee OA
February 16, 2019 - Movement impairments in autism can be reversed through behavioral training
February 16, 2019 - Studies address racial disparities in postpartum period and cardiovascular health
February 16, 2019 - Scientists implicate hidden genes in the severity of autism symptoms
February 16, 2019 - Decreased deep sleep linked to early signs of Alzheimer’s disease
February 16, 2019 - Neuroscientists show how the brain responds to texture
February 16, 2019 - Gilead Announces Topline Data From Phase 3 STELLAR-4 Study of Selonsertib in Compensated Cirrhosis (F4) Due to Nonalcoholic Steatohepatitis (NASH)
February 16, 2019 - What Can I Do About Sweating? (for Teens)
February 16, 2019 - Companies navigate dementia conversations with older workers
February 16, 2019 - Newly developed stem cell technologies show promise for treating PD patients
February 16, 2019 - Collaborative material research could advance self-assembling nanomaterials
February 16, 2019 - Researchers take major step in creating technology that mimics the human brain
February 16, 2019 - Erasing memories associated with cocaine use reduces drug seeking behavior
February 16, 2019 - Artificial intelligence can accurately predict prognosis of ovarian cancer patients
February 16, 2019 - Racial disparities in cancer deaths on the decline for America
February 16, 2019 - FDA authorizes new interoperable insulin pump for children, adults with diabetes
February 16, 2019 - Coexisting Medical Conditions, Smoking Explain PTSD-CVD Link
February 16, 2019 - Skin Cancer Screening: MedlinePlus Lab Test Information
February 16, 2019 - ‘Happiness’ exercises can boost mood in those recovering from substance use disorder
February 16, 2019 - Cell manipulation could soon halt or reverse aging
February 16, 2019 - Pumped Breast Milk Falls Short of Breastfed Version
February 16, 2019 - Men’s porn habits could fuel partners’ eating disorders, study suggests
February 16, 2019 - Rapid progression of age-related diseases may result from formation of vicious cycles
February 16, 2019 - Immune checkpoint molecule protects against future development of cancer
February 16, 2019 - New method produces hydrogels that have properties similar to cells’ environment
February 16, 2019 - $4.1 million funding for heart research on Valentine’s Day
February 16, 2019 - General anesthesia in early infancy unlikely to have lasting effects on developing brains
February 16, 2019 - New breakthroughs for muscular dystrophy research
February 16, 2019 - First Opinion: Embryo editing for higher IQ is a fantasy. Embryo profiling for it is almost here
February 16, 2019 - Vapers develop cancer-related gene deregulation as cigarette smokers
February 16, 2019 - Bringing Antimicrobial Susceptibility Testing (AST) to the Community
February 16, 2019 - Decolonization protocol after hospital discharge can prevent dangerous infections
February 16, 2019 - Children with ASD more likely to face maltreatment, study finds
February 16, 2019 - Study finds genetic vulnerability to use of menthol cigarettes
February 16, 2019 - H-RT should be the standard of care for men with low risk prostate cancer, study shows
February 16, 2019 - New technique using patients’ own modified cells could help treat Crohn’s disease
February 16, 2019 - Therapeutic endoscopy has an expanding role in the treatment of IBD
February 16, 2019 - Blood clot discovery could lead to development of better treatments for blood diseases
February 16, 2019 - Intervention can increase exclusive breastfeeding rates
February 16, 2019 - New project explores how gaming technologies can help cancer patients communicate better
February 16, 2019 - Catalyst Biosciences Presents Updated Data from Its Phase 2/3 Trial of Subcutaneous Marzeptacog Alfa (Activated) in Individuals with Hemophilia A or B with Inhibitors at the 12th Annual EAHAD Congress
February 16, 2019 - Rerouting nerves during amputation reduces phantom limb pain before it starts
February 16, 2019 - A Hormone Produced When We Exercise Might Help Fight Alzheimer’s
February 16, 2019 - Millions of British people breathe toxic air travelling to GPs
February 16, 2019 - Conformance of genetic characteristics found to be crucial for longer preservation of kidney graft
February 16, 2019 - Researchers use optogenetic tool to control, visualize receptor signals in neural cells
February 16, 2019 - New reversible antiplatelet therapy could reduce risk of blood clots, prevent cancer metastasis
February 16, 2019 - Testosterone is not the only hormone needed for penis development
February 16, 2019 - FDA Advisory Committee Recommends Approval of Spravato (esketamine) Nasal Spray for Adults with Treatment-Resistant Depression
February 15, 2019 - Heart surgery technology developed at Baptist Health debuts after years of secrecy
February 15, 2019 - Prescription Opioids Double Risk of Triggering Fatal Car Crash
February 15, 2019 - New study helps doctors better understand high blood pressure in pregnant women
February 15, 2019 - Beta wave control in Parkinson’s diseased brain could be a potential therapy
February 15, 2019 - Media representations of love may justify gender-based violence in young people
February 15, 2019 - Yoga May Help With Rheumatoid Arthritis Symptoms, Severity
February 15, 2019 - Obstructive sleep apnea linked to inflammation, organ dysfunction
February 15, 2019 - Master your mind: A challenge from WELL for Life
February 15, 2019 - Why Some Brain Tumors Respond to Immunotherapy
February 15, 2019 - Must-Reads Of The Week From Brianna Labuskes
February 15, 2019 - Researchers uncover novel mechanism and potential new therapeutic target for Alzheimer’s
February 15, 2019 - Genetic variations in a fourth gene associated with higher ALL risk in Hispanic children
February 15, 2019 - Disruptive behavioral problems in kindergarten linked with lower employment earnings in adulthood
February 15, 2019 - New bioengineered device enhances the production of T-cells
February 15, 2019 - HDL proteome behaves like a tiny Velcro ball that is rolling on surfaces
February 15, 2019 - Puerto Rican children more likely to have poor or decreasing use of asthma inhalers
February 15, 2019 - Quality of patient care does not improve after physician-hospital integration
February 15, 2019 - Synopsys release new software for implant design and patient-specific planning
T-cells engineered to outsmart tumors induce clinical responses in relapsed Hodgkin lymphoma

T-cells engineered to outsmart tumors induce clinical responses in relapsed Hodgkin lymphoma

image_pdfDownload PDFimage_print
Shown on the far right is Catherine ‘Cath’ M. Bollard, M.D., M.B.Ch.B., director of the Children’s Research Institute’s Center for Cancer & Immunology Research and lead study author. Credit: Children’s National Health System

WASHINGTON-(Jan. 16, 2018)-Tumors have come up with ingenious strategies that enable them to evade detection and destruction by the immune system. So, a research team that includes Children’s National Health System clinician-researchers has validated a way to outfox the tumors. They engineered T-cells, essential players in the body’s own immune system, to strip tumors of their self-preservation skill and were able to hold Hodgkin lymphoma at bay in patients with relapsed disease for more than four years. What’s more, they infused patients with the tumor-directed T-cells without requiring “pretreatment” chemotherapy.

Results of the small study were published online Jan. 9, 2018, in the Journal of Clinical Oncology.

“These results come 18 years after this revolutionary approach was first conceptualized. While the study is small, its findings are incredibly encouraging for our families and for the cancer field,” says Catherine “Cath” M. Bollard, M.D., M.B.Ch.B., director of the Children’s Research Institute’s Center for Cancer & Immunology Research and lead study author.

“I started work in this area in 2000,” says Dr. Bollard. “At that time, the oncology community had little enthusiasm for the use of T-cell therapies to treat cancer. Even then, when T-cell therapy was in its relative infancy, some research institutions began to see more than 90 percent complete responses and cure rates in some settings. This most recent study points to the potential of specialized T-cells to fight even more types of immune-evading tumors.”

T-cells seek out and destroy proteins expressed by cancer cells or virus-infected cells, protecting the body from infection and malignancy.

In the dose-escalation study, eight patients with Epstein Barr virus-positive Hodgkin lymphoma received as few as 2 and as many as 12 doses of between 2 × 107 and 1.5 × 108 cells/m2 of specially engineered T-cells. Production of transforming growth factor-β in the immediate vicinity of tumors thwarts tumor-directed therapies by having devastating effects on T-cell function in vivo.

So, the research team forced expression of a dominant-negative TGF-β receptor type 2 (DNRII) onto LMP-specific T-cells (DNRII-LSTs) that were specially designed to seek out and destroy proteins derived from the Epstein Barr virus expressed by the tumor cells. The DNRII expressed by the T-cells allowed the cells to resist the hostile tumor environment and seek out and kill the tumor cells. Seven of the eight patients treated had active disease at the time of T-cell infusion.

“DNRII-LSTs were resistant to otherwise inhibitory concentrations of TGF-β in vitro and retained their ability to kill the cancer cells. After infusion, the signal from the genetically modified T-cells in the peripheral blood increased up to 100-fold,” writes Dr. Bollard and colleagues, adding that “DNRII-LSTs persisted for up to four years. Four of the seven patients with active disease achieved clinical responses that were complete and ongoing in two patients for more than four years, including in one patient who achieved only a partial response to unmodified tumor-directed T-cells.”

The study team writes that their findings underscore the potential utility of expressing DNRII when battling other tumors that have learned to evade the immune system.


Explore further:
Important tumor suppressor discovered in immune cells

More information:
Catherine M. Bollard et al, Tumor-Specific T-Cells Engineered to Overcome Tumor Immune Evasion Induce Clinical Responses in Patients With Relapsed Hodgkin Lymphoma, Journal of Clinical Oncology (2018). DOI: 10.1200/JCO.2017.74.3179

Journal reference:
Journal of Clinical Oncology

Provided by:
Children’s National Medical Center

Tagged with:

About author

Related Articles